Affiliations 

  • 1 Department of Hematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan. [email protected]
  • 2 Department of Pathology, Faculty of Medicine, Al Neelain University, Khartoum, Sudan
  • 3 Department of Family Medicine, Faculty of Medicine, University of Gezira, Wad Medani, Sudan
  • 4 Department of Hematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan
  • 5 Ministry of Health & Population, Hadhramout, Yemen
  • 6 Flow Cytometry Laboratory for Leukemia & Lymphoma Diagnosis, Khartoum, Sudan
BMC Res Notes, 2019 May 23;12(1):282.
PMID: 31122288 DOI: 10.1186/s13104-019-4319-8

Abstract

OBJECTIVE: To investigate the ZAP-70 and CD38 expressions and their combined expressions in Sudanese B-CLL patients and their relationships with clinical and hematological characteristics as well as the disease staging at presentation.

RESULTS: In the present cross-sectional descriptive study, analysis of ZAP-70 expression showed that 36/110 (32.7%) patients positively expressed ZAP-70 and insignificant higher presentation in intermediate and at advanced stages as well as no correlation was seen with hematological parameters and clinical features compared with negatively ZAP-70, on the other hand, 41/110 (37.3%) were CD38+ and no significant correlation was shown with the stage at presentation, clinical characteristics (except Splenomegaly, P = 0.02) and hematological parameters. However, in combined expressions of both ZAP-70 and CD38 together, 20/110 (18.2%) were concordantly ZAP-70+/CD38+, 53/110 (48.2%) concordantly ZAP-70-/CD38- and 37/110 (33.6%) either ZAP-70+ or CD38+, and these three groups showed insignificant correlation with clinical (except Splenomegaly, P = 0.03) and hematological parameters, and the stage at presentation. Our data showed the combined analysis of these two markers, lead to classify our patients into three subgroups (either concordant positive, negative or discordant expressions) with statistically insignificant correlation with clinical presentation (except Splenomegaly), hematological parameters and stage at presentation of B-CLL patients.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.